NASDAQ:CRSP - Crispr Therapeutics Stock Price, Forecast & News

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Crispr Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Wednesday, February, 12th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of ($0.68) by $1.19. The business had revenue of $77 million for the quarter, compared to analysts' expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm's revenue was up 76900.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.92) EPS. View Crispr Therapeutics' Earnings History.

Crispr Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Crispr Therapeutics.

14 brokerages have issued 12 month price objectives for Crispr Therapeutics' stock. Their forecasts range from $59.00 to $104.00. On average, they expect Crispr Therapeutics' stock price to reach $80.41 in the next year. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Price Targets for Crispr Therapeutics.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crispr Therapeutics.

News coverage about CRSP stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Crispr Therapeutics.

Crispr Therapeutics saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 3,090,000 shares, a decrease of 5.8% from the January 30th total of 3,280,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is presently 2.6 days. Approximately 8.3% of the company's stock are sold short. View Crispr Therapeutics' Current Options Chain.

Some companies that are related to Crispr Therapeutics include Moderna (MRNA), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BioNTech (BNTX), BIO-TECHNE (TECH), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Alibaba Group (BABA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Shopify (SHOP), Intel (INTC) and Netflix (NFLX).

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Crispr Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (7.62%), Nikko Asset Management Americas Inc. (5.52%), ARK Investment Management LLC (5.36%), FMR LLC (1.73%), Credit Suisse AG (1.31%) and Abingworth LLP (0.94%). Company insiders that own Crispr Therapeutics stock include Bradley J Phd Bolzon, Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Versant Venture Capital V, LP and Vertex Pharmaceuticals (Europe. View Institutional Ownership Trends for Crispr Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Abingworth LLP, Lord Abbett & CO. LLC, Bank of America Corp DE, Versant Venture Management LLC, SG Americas Securities LLC, Barclays PLC and Credit Suisse AG. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak and Samarth Kulkarni. View Insider Buying and Selling for Crispr Therapeutics.

CRSP stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Nikko Asset Management Americas Inc., Capital International Investors, ARK Investment Management LLC, Laurion Capital Management LP, Columbus Circle Investors and Hodges Capital Management Inc.. View Insider Buying and Selling for Crispr Therapeutics.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRSP stock can currently be purchased for approximately $50.91.

Crispr Therapeutics has a market capitalization of $3.10 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.View Additional Information About Crispr Therapeutics.

The official website for Crispr Therapeutics is http://www.crisprtx.com/.

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]